Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SRRK

SRRK - Scholar Rock Holding Corp Stock Price, Fair Value and News

$40.02-1.78 (-4.26%)
Market Closed

10/100

SRRK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

SRRK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SRRK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRRK Price Action

Last 7 days

-11.6%

Last 30 days

-15.1%

Last 90 days

-14.6%

Trailing 12 Months

15.8%

SRRK RSI Chart

SRRK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRRK Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

-12.16

Price/Sales (Trailing)

402.21

Price/Free Cashflow

-15.29

SRRK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SRRK Fundamentals

SRRK Revenue

Revenue (TTM)

12.7M

Rev. Growth (Yr)

25.45%

Rev. Growth (Qtr)

5.34%

SRRK Earnings

Earnings (TTM)

-377.9M

Earnings Growth (Yr)

-36.88%

Earnings Growth (Qtr)

11.01%

SRRK Profitability

Return on Equity

-153.95%

Return on Assets

-93.49%

Free Cashflow Yield

-6.54%

SRRK Investor Care

Shares Dilution (1Y)

21.34%

Diluted EPS (TTM)

-3.29

SRRK Alerts

  • 4 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202402.7M7.7M12.7M
202247.3M42.7M37.2M33.2M
202115.1M15.8M18.2M18.8M
202022.4M21.3M19.5M15.4M
201900020.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Scholar Rock Holding Corp

SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://scholarrock.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES114

Scholar Rock Holding Corp Frequently Asked Questions

SRRK is the stock ticker symbol of Scholar Rock Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Scholar Rock Holding Corp is 4.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, SRRK's PE ratio (Price to Earnings) is -12.16 and Price to Sales (PS) ratio is 402.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRRK PE ratio will change depending on the future growth rate expectations of investors.